Moreover, anti-ILT4 or anti-PD-L1 treatment markedly decreased the expression and secretion of CCL2 and CCL5 in both tumor cell lines with a synergistic effect in the combination treatment group (Figure S4C-F). Here, LILRB2 is linked to neoplasm.